. 2014 Sep 9;1(3):265–283. doi: 10.2217/hep.14.6

Table 3. . Characteristics of commercially available yttrium-90 microspheres for radioembolization.

	SIR-Spheres^†	TheraSphere^‡
Isotope	⁹⁰Y	⁹⁰Y

Half-life (h)	64.1	64.1

Microsphere material	Resin	Glass

Microsphere diameter (μm)	20–60	20–30

Approximate activity per microsphere (Bq)	50	2500

Number of microspheres per 3 GBq	40–80 × 10⁶	1.2 × 10⁶

Specific gravity (g/ml)	1.6	3.2

Embolic effect	Moderate	Mild

Contrast agent injection	During infusion	None

Indication	USA (FDA PMA): colorectal liver metastases	USA (FDA HDE): hepatocellular carcinoma

^†Sirtex Medical, North Sydney, Australia.

^‡BTG International Canada Inc., Ontario, Canada.

HDE: Humanitarian device exemption; PMA: Premarket approval.